- Report
- January 2024
- 113 Pages
United States
€3185EUR$3,500USD£2,731GBP
- Report
- July 2023
- 218 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- March 2023
- 30 Pages
Global
€11149EUR$12,250USD£9,558GBP
- Report
- January 2023
- 27 Pages
Global
€11149EUR$12,250USD£9,558GBP
- Report
- September 2020
- 65 Pages
Global
€1200EUR$1,318USD£1,028GBP
- Report
- April 2018
United States
From €7276EUR$7,995USD£6,238GBP
- Report
- October 2024
- 87 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- May 2023
- 102 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2024
- 83 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2023
- 112 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- November 2021
- 575 Pages
Global
From €3640EUR$4,000USD£3,121GBP
- Report
- June 2022
- 230 Pages
Global
From €3145EUR$3,456USD£2,696GBP
- Book
- February 2014
- 400 Pages
- Book
- August 2013
- 386 Pages

Etanercept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein that works by blocking the action of tumor necrosis factor (TNF), a protein involved in inflammation. Etanercept is administered by subcutaneous injection and is available in both brand name and generic forms.
Etanercept is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other medications. It is generally well tolerated, with the most common side effects being injection site reactions, headache, and upper respiratory tract infections.
The etanercept market is highly competitive, with several major players. These include Amgen, Pfizer, AbbVie, and Johnson & Johnson. Other companies in the market include Biogen, Merck, and Novartis. Show Less Read more